Introduction
Sarcoidosis is a multi-organ granulomatous disease of unknown aetiology. The incidence of cardiac involvement varies between 5% and 10%, however, these percentages likely underestimate the true prevalence, as the disease course is often subclinical. 1, 2 As cardiac involvement is related with adverse outcome, early diagnosis of cardiac sarcoidosis is crucial. We present a case of a dramatic progression of cardiac sarcoidosis in an asymptomatic patient over a period of 4 years.
Timeline

Case presentation
A 55-year-old male patient, with a history of arterial hypertension and recurrent pulmonary infections, presented with symptoms of a bronchopulmonary infection. Chest X-ray did not reveal a pulmonary infection but was suspicious for a small retro-cardiac nodule. Chest computed tomography (CT) showed several enlarged mediastinal lymph nodes. Subsequent mediastinoscopy revealed the diagnosis of sarcoidosis. Transthoracic echocardiogram (TTE) showed mild concentric left ventricular (LV) hypertrophy, preserved systolic and diastolic function, and absence of valvular abnormalities and pulmonary hypertension. 18 F-fluorodeoxyglucose-positron emission tomographycomputed tomography ( 18 F-FDG-PET-CT) revealed several foci of increased myocardial FDG uptake. Cardiac magnetic resonance (CMR) showed normovolaemic and normokinetic ventricles with borderline increased septal wall thickness. At late gadolinium enhancement (LGE)-CMR, multifocal subepicardial enhancement was present in the basal anterior/inferolateral and mid to apical lateral LV wall ( Figure 1A) . As LGE-lesions spatially correlated with PET lesions, they were considered to represent active inflammation. Electrocardiography (ECG) findings were not specific, exercise stress test did not induce any chest pain or ECG changes, Holter monitoring, and cardiac biomarkers were also unremarkable ( Figure 2 , Table 1 ). On initial examination: blood pressure (BP)-140/80 mmHg, heart rate (HR)-66/ min, oxygen saturation-98%, normal heart and lung auscultation, no ankle oedema, and no lymphadenopathy. Bronchoscopy, spirometry, and neurologic and ophthalmologic investigations were negative. Because of the lack of clinical symptoms and cardiac dysfunction, no treatment was initiated, but it was decided to closely follow-up the patient. Although a first follow-up CMR (2015) showed comparable findings, the 2016 CMR revealed new myocardial lesions in the RV outflow tract and inferior wall ( Figure 1B, C) . The ventricular function was normal, and the patient did not experience cardiac complaints and tolerated physical exercise well. In 2017, patient was still asymptomatic, there was no evidence of disease progression and CMR was substituted with TTE.
In October 2018, the patient presented with onset of dyspnoea and dry cough. At physical examination: BP-145/95 mmHg, HR-74/ min, low-pitched breath sound, the rest was comparable to the examination at initial presentation. Electrocardiography showed an atrioventricular (AV) block Grade 1 ( Figure 2) . A new CMR showed important disease progression with increase in myocardial wall thickness, increase in size of the LGE regions, and presence of several new lesions (i.e. anterolateral/anteroseptal LV wall, anterior RV wall, and left atrium). Total LGE volume (37% of LV-mass) corresponded to a nearly three-fold increase compared to 2014 CMR. The LGE regions showed prolonged T1-relaxation time (range 1060-1090 ms; normal values at 1.5 T 997 ± 19ms) and increased extracellular volume values (range 30-60%; normal values 22-28%; Figure 1E ). Remarkably, the global ventricular function was still low normal (ejection fraction (EF) 50%) and cardiac biomarkers remained within normal limits ( Table 1) . 18 F-FDG PET-CT scan showed multifocal areas with increased FDG uptake, nicely matching with the LGE areas ( Figure 3) . Moreover, strongly increased FDG uptake was present in abdominal and thoracic lymphadenopathies and to a lesser extent in the pulmonary parenchyma as well, consistent with nodal and pulmonary involvement. Subsequent spirometry revealed decreased pulmonary diffusion capacity. Holter monitoring as well as electrophysiology (EPI) study could not reveal (inducible) ventricular arrhythmias. It was decided to initiate steroid treatment (start dose: 32 mg/day), which was reduced to 24 mg/day at the latest (4-month) follow-up. Although the patient still complained of dyspnoea, physical examination and laboratory investigations (NT-proBNP-201 ng/L, hs troponine-0, 007 mcg/L) were not remarkable. Echocardiography showed decreased systolic LV function (EF 45%). Although a new EPI study could not induce ventricular arrhythmias, Holter monitoring showed frequent polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia. Because of the increased risk of malignant ventricular arrhythmias the patient received implantation of cardioverter-defibrillator.
Discussion
Correct decision making in patients with cardiac sarcoidosis is crucial but often challenging, as shown in this case. As our patient had no cardiac symptoms, no evidence of ventricular arrhythmia or conduction disturbances and a preserved cardiac function during the first 3 years, 
no steroid treatment was initiated. On the other hand, LGE-CMR showed important disease progression, in particular in the last 2 years. This raises the key question, whether and when to initiate treatment to prevent or slow-down disease progression and to reduce the risk of malignant ventricular arrhythmias. While in some studies presence of LGE and FDG-active lesions in cardiac sarcoidosis patients was associated with adverse events, other studies showed a more favourable outcome. 3, 4 Furthermore, several small studies demonstrated that patients with (relatively) preserved LV function may benefit from early corticosteroid therapy. However, all these patients presented with either AV block or ventricular arrhythmia. 5, 6 Decision making is further complicated by the lack of evidencebased studies. According to the Japanese guidelines, cardiac sarcoidosis patients with evidence of active lesions are candidates for steroid treatment. 7 According to HRS Expert Consensus Group, treatment should be started at the presence of heart block or ventricular ectopy. 1 As LGE-CMR is able to depict focal myocardial fibrosis, it is increasingly used to image sarcoidosis patients and is considered by some members of the HRS Expert Consensus Group as a prognostic criterion. 1, 8 However, it is important to emphasize, as shown in our patient, that LGE does not necessarily reflect scarring, but may also represent active, ongoing inflammation. Arguments in favour are the perfect match with the PET lesions ( Figure 3) . This underscores the need for complementary tissue characterization. Nowadays besides T2-weighted imaging, novel quantitative techniques such as T1 and T2 mapping, or combined PET/CMR imaging are preferable. 9, 10 Lesions with active inflammation typically have increased T1 and T2 values.
Use of CMR and PET-CT was of great help in our asymptomatic patient, not only to depict and to tissue characterize cardiac sarcoidosis, but also to monitor disease progression over time. However, as mentioned above, clinical decision making may be challenged if the extent of myocardial damage at imaging is out of proportion to the patient's clinical symptoms, exercise tolerance, preserved cardiac biomarkers, and lack of cardiac dysfunction. Therefore, further studies are needed to better understand how these imaging findings can be integrated in guidelines for cardiac sarcoidosis management.
Conclusions
Complementary value of CMR and FDG-PET is appealing to better understand the natural evolution of cardiac sarcoidosis as shown in this asymptomatic patient. A better understanding of disease progression may be helpful in the management of such patients. Natural evolution of cardiac sarcoidosis in an asymptomatic patient
